Pharsight

Drug Patents Expiring in 2039

1. Airduo Digihaler patents expiration

AIRDUO DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000653

(Pediatric)

TEVA PHARM Inhaler
Jun, 2039

(15 years from now)

US11344685 TEVA PHARM Drug delivery device with electronics
Sep, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

2. Anjeso patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458145 BAUDAX Methods of administering intravenous meloxicam in a bolus dose
Mar, 2039

(15 years from now)

US10881663 BAUDAX Method of treating pain in elderly patients with mild renal impairment
Mar, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Feb 20, 2023

Drugs and Companies using MELOXICAM ingredient

Market Authorisation Date: 20 February, 2020

Treatment: Management of moderate-to-severe pain by injection; Management of moderate-to-severe pain by intravenous injection in patients with mild renal impairment

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ANJESO family patents

Family Patents

3. Annovera patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10765628 THERAPEUTICSMD INC Method of providing birth control
Feb, 2039

(14 years from now)

US10632066 THERAPEUTICSMD INC Method of providing birth control
Feb, 2039

(14 years from now)

US10780047 THERAPEUTICSMD INC Method of providing birth control
Feb, 2039

(14 years from now)

US11529308 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(15 years from now)

US10918649 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(15 years from now)

US10925882 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(15 years from now)

US10940157 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 10, 2023

Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient

NCE-1 date: 2022-08-10

Market Authorisation Date: 10 August, 2018

Treatment: Method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles; Method of...

Dosage: RING;VAGINAL

More Information on Dosage

ANNOVERA family patents

Family Patents

4. Annovera patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11850251 MAYNE PHARMA System for providing birth control
Jun, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 10, 2023

Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient

NCE-1 date: 2022-08-10

Market Authorisation Date: 10 August, 2018

Treatment: Method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg of ethinyl estradiol for up to 1thirteen 21/7-day (in/out) cycles

Dosage: RING;VAGINAL

More Information on Dosage

ANNOVERA family patents

Family Patents

5. Aristada patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11273158 ALKERMES INC Aripiprazole dosing strategy
Apr, 2039

(15 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ARISTADA family patents

Family Patents

6. Aristada Initio Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11273158 ALKERMES INC Aripiprazole dosing strategy
Apr, 2039

(15 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 29 June, 2018

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ARISTADA INITIO KIT family patents

Family Patents

7. Armonair Digihaler patents expiration

ARMONAIR DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11357935

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Mar, 2039

(15 years from now)

US11000653

(Pediatric)

TEVA PHARM Inhaler
Jun, 2039

(15 years from now)

US11344685 TEVA PHARM Drug delivery device with electronics
Sep, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

8. Baqsimi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10765602 ELI LILLY AND CO Medication delivery systems and methods
Sep, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Jul 24, 2022

Drugs and Companies using GLUCAGON ingredient

Market Authorisation Date: 24 July, 2019

Treatment: NA

Dosage: POWDER;NASAL

More Information on Dosage

BAQSIMI family patents

Family Patents

9. Brexafemme patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11534433 SCYNEXIS Antifungal agents with enhanced activity in acidic pH
Jun, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 1, 2026
New Indication (I) Nov 30, 2025
Generating Antibiotic Incentives Now (GAIN) Jun 1, 2031

Drugs and Companies using IBREXAFUNGERP CITRATE ingredient

NCE-1 date: 2030-06-01

Market Authorisation Date: 01 June, 2021

Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc); Reduction in the incidence of recurrent vulvovaginal candidiasis (rvvc) in adult and post-menarchal pediatr...

Dosage: TABLET;ORAL

More Information on Dosage

BREXAFEMME family patents

Family Patents

10. Bylvay patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10975046 ALBIREO Crystal modifications of odevixibat
Jun, 2039

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11801226 ALBIREO Pharmaceutical formulation of odevixibat
Jun, 2039

(15 years from now)

US11365182 ALBIREO Crystal modifications of odevixibat
Jun, 2039

(15 years from now)

US11802115 ALBIREO Pharmaceutical formulation of odevixibat
Jun, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 20, 2026
Orphan Drug Exclusivity (ODE) Jul 20, 2028
New Indication (I) Jun 13, 2026

Drugs and Companies using ODEVIXIBAT ingredient

NCE-1 date: 2025-07-20

Market Authorisation Date: 20 July, 2021

Treatment: Method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); Method of reducing serum bile acids in patients 3 months or older sufferi...

Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL

More Information on Dosage

BYLVAY family patents

Family Patents

11. Camcevi Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11717555 ACCORD Pharmaceutical compositions having a selected release duration
Jan, 2039

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) May 25, 2024

Drugs and Companies using LEUPROLIDE MESYLATE ingredient

Market Authorisation Date: 25 May, 2021

Treatment: NA

Dosage: EMULSION;SUBCUTANEOUS

More Information on Dosage

CAMCEVI KIT family patents

Family Patents

12. Caplyta patents expiration

Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11690842 INTRA-CELLULAR Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
Aug, 2039

(15 years from now)

US11052084 INTRA-CELLULAR Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
Aug, 2039

(15 years from now)

US10695345 INTRA-CELLULAR Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
Aug, 2039

(15 years from now)

US11806348 INTRA-CELLULAR Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate
Aug, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 20, 2024
New Indication (I) Dec 17, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: 2023-12-21

Market Authorisation Date: 20 December, 2019

Treatment: Treatment of bipolar depression mediated by the 5-ht2a receptor, serotonin transporter, and/or dopamine d1/d2 signaling pathways; Treatment of schizophrenia mediated by the 5-ht2a receptor, serotonin ...

Dosage: CAPSULE;ORAL

More Information on Dosage

CAPLYTA family patents

Family Patents

13. Combogesic patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11534407 AFT PHARMS LTD Pharmaceutical compostion containing acetominophen and ibuprofen
Feb, 2039

(15 years from now)

US11197830 AFT PHARMS LTD Pharmaceutical composition containing acetaminophen and ibuprofen
Feb, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 1, 2026

Drugs and Companies using ACETAMINOPHEN; IBUPROFEN ingredient

Market Authorisation Date: 01 March, 2023

Treatment: A method of treating mild to moderate acute pain in adults by administering 975-1000 mg of acetaminophen and 292.5-300 mg of ibuprofen in a single administration

Dosage: TABLET;ORAL

More Information on Dosage

COMBOGESIC family patents

Family Patents

14. Cosela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529352 G1 THERAP Preservation of immune response during chemotherapy regimens
Jul, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 12, 2026

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

NCE-1 date: 2025-02-12

Market Authorisation Date: 12 February, 2021

Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen that includes an immune checkpoint inhi...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

COSELA family patents

Family Patents

15. Cuvrior patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10988436 ORPHALAN Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
May, 2039

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11072577 ORPHALAN Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
May, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Apr 28, 2025
Orphan Drug Exclusivity (ODE) Apr 28, 2029

Drugs and Companies using TRIENTINE TETRAHYDROCHLORIDE ingredient

Market Authorisation Date: 28 April, 2022

Treatment: A method for the treatment of adult patients with stable wilson’s disease who are de-coppered and tolerant to penicillamine

Dosage: TABLET;ORAL

How can I launch a generic of CUVRIOR before it's drug patent expiration?
More Information on Dosage

CUVRIOR family patents

Family Patents

16. Dexycu Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11097061 EYEPOINT PHARMS Systems, kits and methods for loading and delivering a small volume dose from a syringe
Jun, 2039

(15 years from now)

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 09 February, 2018

Treatment: A method of loading medication into a syringe and delivering the medication to a treatment site

Dosage: SUSPENSION;INTRAOCULAR

More Information on Dosage

DEXYCU KIT family patents

Family Patents

17. Dhivy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11439613 AVION PHARMS Levodopa fractionated dose composition and use
Mar, 2039

(15 years from now)

US11819485 AVION PHARMS Levodopa fractionated dose composition and use
Mar, 2039

(15 years from now)

US11033521 AVION PHARMS Levodopa fractionated dose composition and use
Mar, 2039

(15 years from now)

Drugs and Companies using CARBIDOPA; LEVODOPA ingredient

Market Authorisation Date: 12 November, 2021

Treatment: Treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease;...

Dosage: TABLET;ORAL

More Information on Dosage

DHIVY family patents

Family Patents

18. Elcys patents expiration

ELCYS Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10653719 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US11826383 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US11684636 EXELA PHARMA Stable, highly pure l-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US11679125 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US11642370 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US11510942 EXELA PHARMA NA
Jan, 2039

(14 years from now)

US11510941 EXELA PHARMA NA
Jan, 2039

(14 years from now)

US10912795 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10905713 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10933089 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10918662 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10583155 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10478453 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10905714 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US11648262 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 April, 2019

Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of ELCYS before it's drug patent expiration?
More Information on Dosage

ELCYS family patents

Family Patents

19. Elucirem patents expiration

ELUCIREM's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10973934 GUERBET Gadolinium bearing PCTA-based contrast agents
Aug, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 21, 2027

Drugs and Companies using GADOPICLENOL ingredient

NCE-1 date: 2026-09-21

Market Authorisation Date: 21 September, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ELUCIREM family patents

Family Patents

20. Epidiolex patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11207292 GW RES LTD Cannabidiol preparations and its uses
Apr, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jul 31, 2027
M (M) Oct 20, 2026

Drugs and Companies using CANNABIDIOL ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Use for the treatment of seizures associated with dravet syndrome; Use for the treatment of seizures associated with tuberous sclerosis complex; Use for the treatment of seizures associated with lenno...

Dosage: SOLUTION;ORAL

How can I launch a generic of EPIDIOLEX before it's drug patent expiration?
More Information on Dosage

EPIDIOLEX family patents

Family Patents

21. Epidiolex patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11865102 JAZZ PHARMS RES Cannabidiol preparations and its uses
Apr, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jul 31, 2027
M (M) Oct 20, 2026

Drugs and Companies using CANNABIDIOL ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Use for the treatment of seizures in patients with dravet syndrome; Use for the treatment of seizures associated with lennox-gastaut syndrome; Use for the treatment of seizures associated with tuberou...

Dosage: SOLUTION;ORAL

How can I launch a generic of EPIDIOLEX before it's drug patent expiration?
More Information on Dosage

EPIDIOLEX family patents

Family Patents

22. Epinephrine In 0.9 Percent Sodium Chloride patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11083698 PAR STERILE PRODUCTS Epinephrine compositions and containers
Mar, 2039

(15 years from now)

US10653646 PAR STERILE PRODUCTS Epinephrine compositions and containers
Mar, 2039

(15 years from now)

US11207280 PAR STERILE PRODUCTS Epinephrine compositions and containers
Mar, 2039

(15 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 21 April, 2023

Treatment: To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

EPINEPHRINE IN 0.9 PERCENT SODIUM CHLORIDE family patents

Family Patents

23. Farxiga patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11826376 ASTRAZENECA AB Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same
Jul, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Apr 30, 2024
M (M) May 8, 2026

Drugs and Companies using DAPAGLIFLOZIN ingredient

Market Authorisation Date: 08 January, 2014

Treatment: Reduce the risk of cardiovascular death and hospitalization for heart failure and urgent heart failure visits in adults with heart failure with preserved ejection fraction and without type ii diabetes

Dosage: TABLET;ORAL

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

24. Focinvez patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11065256 SPES PHARMS Administration and dosage of diaminophenothiazines
Jan, 2039

(14 years from now)

Drugs and Companies using FOSAPREPITANT DIMEGLUMINE ingredient

Market Authorisation Date: 22 August, 2023

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

FOCINVEZ family patents

Family Patents

25. Focinvez patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11065265 STERISCIENCE Compositions of fosaprepitant and methods of preparation
Jan, 2039

(14 years from now)

Drugs and Companies using FOSAPREPITANT DIMEGLUMINE ingredient

Market Authorisation Date: 22 August, 2023

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

FOCINVEZ family patents

Family Patents

26. Fotivda patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11504365 AVEO PHARMS NA
Nov, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 10, 2026

Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient

NCE-1 date: 2025-03-10

Market Authorisation Date: 10 March, 2021

Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally f...

Dosage: CAPSULE;ORAL

More Information on Dosage

FOTIVDA family patents

Family Patents

27. Galafold patents expiration

Can you believe GALAFOLD received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11826360 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
Feb, 2039

(15 years from now)

US11622962 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
Mar, 2039

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11357784 AMICUS THERAP US Use of migalastat for treating Fabry disease in pregnant patients
Feb, 2039

(14 years from now)

US11642334 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
Feb, 2039

(15 years from now)

US11633388 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
Mar, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 10, 2025

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients

Dosage: CAPSULE;ORAL

How can I launch a generic of GALAFOLD before it's drug patent expiration?
More Information on Dosage

GALAFOLD family patents

Family Patents

28. Gavreto patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11273160 GENENTECH INC RET inhibitor for use in treating cancer having a RET alteration
Apr, 2039

(15 years from now)

US11872192 GENENTECH INC RET inhibitor for use in treating cancer having a RET alteration
Apr, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 4, 2025
Orphan Drug Exclusivity (ODE) Sep 4, 2027

Drugs and Companies using PRALSETINIB ingredient

NCE-1 date: 2024-09-04

Market Authorisation Date: 04 September, 2020

Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test

Dosage: CAPSULE;ORAL

More Information on Dosage

GAVRETO family patents

Family Patents

29. Igalmi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792246 BIOXCEL Film formulations containing dexmedetomidine and methods of producing them
Jun, 2039

(15 years from now)

US11478422 BIOXCEL Film formulations containing dexmedetomidine and methods of producing them
Jun, 2039

(15 years from now)

US11497711 BIOXCEL NA
Jun, 2039

(15 years from now)

US11517524 BIOXCEL NA
Jun, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Apr 5, 2025

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 April, 2022

Treatment: Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual administration

Dosage: FILM;BUCCAL, SUBLINGUAL

More Information on Dosage

IGALMI family patents

Family Patents

30. Ingrezza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11026931 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Aug, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 18, 2030
New Indication (I) Aug 18, 2026

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

Market Authorisation Date: 11 April, 2017

Treatment: Treatment of tardive dyskinesia

Dosage: CAPSULE;ORAL

How can I launch a generic of INGREZZA before it's drug patent expiration?
More Information on Dosage

INGREZZA family patents

Family Patents

31. Inrebic patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11400092 IMPACT Methods of treating myeloproliferative disorders
Sep, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 16, 2026
New Chemical Entity Exclusivity (NCE) Aug 16, 2024

Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient

NCE-1 date: 2023-08-17

Market Authorisation Date: 16 August, 2019

Treatment: Treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, monitoring thiamine levels and administering thiamine or a thiamine equivalent

Dosage: CAPSULE;ORAL

More Information on Dosage

INREBIC family patents

Family Patents

32. Jatenzo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11564933 TOLMAR Methods of treating testosterone deficiency
Apr, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 27, 2022

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 27 March, 2019

Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone

Dosage: CAPSULE;ORAL

More Information on Dosage

JATENZO family patents

Family Patents

33. Katerzia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799453 AZURITY Amlodipine formulations
Apr, 2039

(15 years from now)

Drugs and Companies using AMLODIPINE BENZOATE ingredient

Market Authorisation Date: 08 July, 2019

Treatment: NA

Dosage: SUSPENSION;ORAL

How can I launch a generic of KATERZIA before it's drug patent expiration?
More Information on Dosage

KATERZIA family patents

Family Patents

34. Khapzory patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11541012 ACROTECH BIOPHARMA Compositions comprising disodium levofolinate
Mar, 2039

(15 years from now)

Drugs and Companies using LEVOLEUCOVORIN ingredient

Market Authorisation Date: 19 October, 2018

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

KHAPZORY family patents

Family Patents

35. Konvomep patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103492 AZURITY Compositions and kits for omeprazole suspension
Jul, 2039

(15 years from now)

US11633478 AZURITY Compositions and kits for Omeprazole suspension
Jul, 2039

(15 years from now)

US10751333 AZURITY Compositions and kits for omeprazole suspension
Jul, 2039

(15 years from now)

Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient

Market Authorisation Date: 30 August, 2022

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage

KONVOMEP family patents

Family Patents

36. Likmez patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11541035 SAPTALIS PHARMS Oral formulations of metronidazole and methods of treating an infection using same
Oct, 2039

(15 years from now)

Drugs and Companies using METRONIDAZOLE ingredient

Market Authorisation Date: 22 September, 2023

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

LIKMEZ family patents

Family Patents

37. Lumason patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11723869 BRACCO Freeze-dried product and gas-filled microvesicles suspension
May, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Nov 13, 2022

Drugs and Companies using SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES ingredient

Market Authorisation Date: 15 October, 2014

Treatment: Use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border; Use in ultrasonog...

Dosage: FOR SUSPENSION;INTRAVENOUS

More Information on Dosage

LUMASON family patents

Family Patents

38. Lytgobi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11833151 TAIHO ONCOLOGY Pharmaceutical composition including sodium alkyl sulfate
Nov, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 30, 2027
Orphan Drug Exclusivity (ODE) Sep 30, 2029

Drugs and Companies using FUTIBATINIB ingredient

NCE-1 date: 2026-09-30

Market Authorisation Date: 30 September, 2022

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

LYTGOBI family patents

Family Patents

39. Lyvispah patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11654124 AMNEAL Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
Jul, 2039

(15 years from now)

US10792262 AMNEAL Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
Jul, 2039

(15 years from now)

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 22 November, 2021

Treatment: Method for treating spasticity

Dosage: GRANULES;ORAL

More Information on Dosage

LYVISPAH family patents

Family Patents

40. Mounjaro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 2026-05-13

Market Authorisation Date: 13 May, 2022

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

MOUNJARO family patents

Family Patents

41. Norepinephrine Bitartrate In 0.9% Sodium Chloride patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888534 INFORLIFE Storage stable ready-to-use norepinephrine aqueous solutions in flexible plastic bags
Apr, 2039

(15 years from now)

Drugs and Companies using NOREPINEPHRINE BITARTRATE ingredient

Market Authorisation Date: 15 September, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE family patents

Family Patents

42. Nouress patents expiration

NOURESS Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10905713 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10933089 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10653719 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10912795 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10918662 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10583155 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10478453 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10905714 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US11510942 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US11510941 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Mar, 2039

(15 years from now)

US10543186 BAXTER HLTHCARE CORP Cysteine composition and injection
Mar, 2039

(15 years from now)

US10702490 BAXTER HLTHCARE CORP Cysteine composition and injection
Mar, 2039

(15 years from now)

US10493051 BAXTER HLTHCARE CORP Cysteine composition and injection
Mar, 2039

(15 years from now)

US11045438 BAXTER HLTHCARE CORP Cysteine composition and injection
Mar, 2039

(15 years from now)

Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 December, 2019

Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition; Method of intravenously administering a diluted cysteine hydrochloride solution to a neonate in need ther...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

NOURESS family patents

Family Patents

43. Nurtec Odt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11083724 PFIZER Rimegepant for CGRP related disorders
Mar, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 27, 2025
New Indication (I) May 27, 2024

Drugs and Companies using RIMEGEPANT SULFATE ingredient

NCE-1 date: 2024-02-28

Market Authorisation Date: 27 February, 2020

Treatment: Acute treatment of migraine with or without aura in adults; Preventive treatment of episodic migraine in adults

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

NURTEC ODT family patents

Family Patents

44. Ogsiveo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10941118 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

US10710966 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

US10590087 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

US11845732 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11884634 SPRINGWORKS Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
Aug, 2039

(15 years from now)

US11820748 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

US11884635 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 27, 2030
New Chemical Entity Exclusivity (NCE) Nov 27, 2028

Drugs and Companies using NIROGACESTAT HYDROBROMIDE ingredient

NCE-1 date: 2027-11-28

Market Authorisation Date: 27 November, 2023

Treatment: Treatment of adult patients with progressing desmoid tumors

Dosage: TABLET;ORAL

More Information on Dosage

OGSIVEO family patents

Family Patents

45. Omlonti patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11666563 SANTEN Pharmaceutical preparation containing pyridyl aminoacetic acid compound
Jul, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 22, 2027

Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient

NCE-1 date: 2026-09-22

Market Authorisation Date: 22 September, 2022

Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

OMLONTI family patents

Family Patents

46. Oriahnn (copackaged) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11542239 ABBVIE Elagolix sodium compositions and processes
Jul, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023
New Product (NP) May 29, 2023

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

NCE-1 date: 2022-07-23

Market Authorisation Date: 29 May, 2020

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of ORIAHNN (COPACKAGED) before it's drug patent expiration?
More Information on Dosage

ORIAHNN (COPACKAGED) family patents

Family Patents

47. Orilissa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11542239 ABBVIE Elagolix sodium compositions and processes
Jul, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: 2022-07-23

Market Authorisation Date: 23 July, 2018

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ORILISSA before it's drug patent expiration?
More Information on Dosage

ORILISSA family patents

Family Patents

48. Orladeyo patents expiration

Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10662160 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11618733 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(15 years from now)

US11117867 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 3, 2027
New Chemical Entity Exclusivity (NCE) Dec 3, 2025

Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient

NCE-1 date: 2024-12-03

Market Authorisation Date: 03 December, 2020

Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and ped...

Dosage: CAPSULE;ORAL

More Information on Dosage

ORLADEYO family patents

Family Patents

49. Ozobax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610502 METACEL PHARMS LLC Oral baclofen solutions
Aug, 2039

(15 years from now)

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 18 September, 2019

Treatment: Treatment of spasticity

Dosage: SOLUTION;ORAL

How can I launch a generic of OZOBAX before it's drug patent expiration?
More Information on Dosage

OZOBAX family patents

Family Patents

50. Pedmark patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11617793 FENNEC PHARMS INC Anhydrous sodium thiosulfate and formulations thereof
Jul, 2039

(15 years from now)

US11291728 FENNEC PHARMS INC Anhydrous sodium thiosulfate and formulations thereof
Jul, 2039

(15 years from now)

US11510984 FENNEC PHARMS INC Anhydrous sodium thiosulfate and formulations thereof
Jul, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Sep 20, 2025
Orphan Drug Exclusivity (ODE) Sep 20, 2029

Drugs and Companies using SODIUM THIOSULFATE ingredient

Market Authorisation Date: 20 September, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of PEDMARK before it's drug patent expiration?
More Information on Dosage

PEDMARK family patents

Family Patents

51. Pemazyre patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11466004 INCYTE CORP Solid forms of an FGFR inhibitor and processes for preparing the same
May, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 17, 2025
Orphan Drug Exclusivity (ODE) Aug 26, 2029
New Indication (I) Aug 26, 2025

Drugs and Companies using PEMIGATINIB ingredient

NCE-1 date: 2024-04-17

Market Authorisation Date: 17 April, 2020

Treatment: Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering once daily a tablet containing about 0.5 mg ...

Dosage: TABLET;ORAL

More Information on Dosage

PEMAZYRE family patents

Family Patents

52. Potassium Phosphates patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10632150 CMP DEV LLC Potassium phosphates composition for injection
Apr, 2039

(15 years from now)

Drugs and Companies using POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC ingredient

Market Authorisation Date: 19 September, 2019

Treatment: Potassium phosphates injection is indicated as a source of phosphorus in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of age and older

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

POTASSIUM PHOSPHATES family patents

Family Patents

53. Proair Digihaler patents expiration

PROAIR DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11344685 TEVA BRANDED PHARM Drug delivery device with electronics
Sep, 2039

(15 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 31 March, 2015

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

PROAIR DIGIHALER family patents

Family Patents

54. Qvar Redihaler patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792447 NORTON WATERFORD Breath actuated inhaler
Jan, 2039

(14 years from now)

US11559637 NORTON WATERFORD Inhalers and related methods
Jul, 2039

(15 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 03 August, 2017

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

QVAR REDIHALER family patents

Family Patents

55. Radicava Ors patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11478450 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(15 years from now)

US11241416 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(15 years from now)

US11826352 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(15 years from now)

US10987341 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) May 12, 2025

Drugs and Companies using EDARAVONE ingredient

Market Authorisation Date: 12 May, 2022

Treatment: Treatment of amyotrophic lateral sclerosis

Dosage: SUSPENSION;ORAL

How can I launch a generic of RADICAVA ORS before it's drug patent expiration?
More Information on Dosage

RADICAVA ORS family patents

Family Patents

56. Rezlidhia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10532047 RIGEL PHARMS INC Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
May, 2039

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11376246 RIGEL PHARMS INC Inhibiting mutant IDH-1
May, 2039

(15 years from now)

US10959994 RIGEL PHARMS INC Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
May, 2039

(15 years from now)

US11497743 RIGEL PHARMS INC Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation
May, 2039

(15 years from now)

US11013733 RIGEL PHARMS INC Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
May, 2039

(15 years from now)

US11013734 RIGEL PHARMS INC Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
May, 2039

(15 years from now)

US11738018 RIGEL PHARMS INC Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
Jul, 2039

(15 years from now)

US11723905 RIGEL PHARMS INC Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
Nov, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 1, 2027
Orphan Drug Exclusivity (ODE) Dec 1, 2029

Drugs and Companies using OLUTASIDENIB ingredient

NCE-1 date: 2026-12-01

Market Authorisation Date: 01 December, 2022

Treatment: A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehydrogenase-1 (idh1) mutation; A method of treating a cancer characterized by an idh1 mutation where the cancer is ac...

Dosage: CAPSULE;ORAL

More Information on Dosage

REZLIDHIA family patents

Family Patents

57. Sotalol Hydrochloride patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799138 ALTATHERA PHARMS LLC Method of administering sotalol IV/switch
Apr, 2039

(15 years from now)

US11583216 ALTATHERA PHARMS LLC Method of administering sotalol IV/switch
Aug, 2039

(15 years from now)

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Market Authorisation Date: 02 July, 2009

Treatment: Use for loading dose in patients with symptomatic afib/afl who are currently in sinus rhythm or for the treatment of life-threatening ventricular tachycardia; Intravenous sotalol dosing regimen for us...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

SOTALOL HYDROCHLORIDE family patents

Family Patents

58. Spy Agent Green Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11712320 NOVADAQ TECH Methods and systems to automate surgical interventions
Jul, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Jun 5, 2026

Drugs and Companies using INDOCYANINE GREEN ingredient

Market Authorisation Date: 21 November, 2018

Treatment: NA

Dosage: POWDER;INTRAVENOUS, INTERSTITIAL

How can I launch a generic of SPY AGENT GREEN KIT before it's drug patent expiration?
More Information on Dosage

SPY AGENT GREEN KIT family patents

Family Patents

59. Sunosi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11560354 AXSOME MALTA Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof
Mar, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 2023-06-18

Market Authorisation Date: 17 June, 2019

Treatment: Treatment of excessive daytime sleepiness by adminstering a composition comprising solriamfetol hydrochloride and 2-chloropropane, wherein the composition comprises less than about 5 ppm 2-chloropropa...

Dosage: TABLET;ORAL

How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage

SUNOSI family patents

Family Patents

60. Testosterone Cypionate patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11642355 SLAYBACK PHARMA LLC Pharmaceutical compositions of testosterone
Mar, 2039

(15 years from now)

US11311554 SLAYBACK PHARMA LLC Pharmaceutical compositions of testosterone
Mar, 2039

(15 years from now)

Drugs and Companies using TESTOSTERONE CYPIONATE ingredient

Market Authorisation Date: 02 June, 2022

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR

More Information on Dosage

TESTOSTERONE CYPIONATE family patents

Family Patents

61. Tibsovo patents expiration

Can you believe TIBSOVO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10980788 SERVIER Therapy for treating malignancies
Jun, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 24, 2030
New Indication (I) May 25, 2025

Drugs and Companies using IVOSIDENIB ingredient

Market Authorisation Date: 20 July, 2018

Treatment: A method of treating previously treated, locally advanced or metastatic cholangiocarcinoma characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a ...

Dosage: TABLET;ORAL

How can I launch a generic of TIBSOVO before it's drug patent expiration?
More Information on Dosage

TIBSOVO family patents

Family Patents

62. Tirosint-sol patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11241382 IBSA Administration regimen of compositions of T4 thyroid hormone with high oral absorption
Sep, 2039

(15 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 15 December, 2016

Treatment: Treatment of hypothyroidism by oral administration of l-thyroxine to a patient on an empty stomach 15 minutes before breakfast; Treatment of pituitary thyrotropin suppression by oral administration of...

Dosage: SOLUTION;ORAL

How can I launch a generic of TIROSINT-SOL before it's drug patent expiration?
More Information on Dosage

TIROSINT-SOL family patents

Family Patents

63. Trudhesa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11185497 IMPEL NEUROPHARMA Intranasal delivery of dihydroergotamine by precision olfactory device
Jan, 2039

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Sep 2, 2024

Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient

Market Authorisation Date: 02 September, 2021

Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

TRUDHESA family patents

Family Patents

64. Upneeq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11541036 RVL PHARMS NA
Dec, 2039

(15 years from now)

US11701343 RVL PHARMS Compositions and methods for treating ocular disorders
Dec, 2039

(15 years from now)

US11311515 RVL PHARMS Oxymetazoline compositions
Dec, 2039

(15 years from now)

US10799481 RVL PHARMS Compositions and methods for treating ocular disorders
Dec, 2039

(15 years from now)

US11103482 RVL PHARMS Oxymetazoline compositions
Dec, 2039

(15 years from now)

US10898573 RVL PHARMS Oxymetazoline compositions
Dec, 2039

(15 years from now)

US11324722 RVL PHARMS Compositions and methods for treating ocular disorders
Dec, 2039

(15 years from now)

US10814001 RVL PHARMS Oxymetazoline compositions
Dec, 2039

(15 years from now)

US10940138 RVL PHARMS Compositions and methods for treating ocular disorders
Dec, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Jul 8, 2023

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 July, 2020

Treatment: Method of treating blepharoptosis

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage

UPNEEQ family patents

Family Patents

65. Vabomere patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11376237 REMPEX Methods of treating bacterial infections
Apr, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 29, 2022
Generating Antibiotic Incentives Now (GAIN) Aug 29, 2027

Drugs and Companies using MEROPENEM; VABORBACTAM ingredient

NCE-1 date: 2026-08-29

Market Authorisation Date: 29 August, 2017

Treatment: Treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli,klebsiella pneumonia,enterobacter cloacae species...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

VABOMERE family patents

Family Patents

66. Veklury patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11266681

(Pediatric)

GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jan, 2039

(14 years from now)

US10675296

(Pediatric)

GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jan, 2039

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 22, 2025
New Patient Population (NPP) Apr 25, 2025
New Dosing Schedule (D) Jan 21, 2025
M (M) Jul 13, 2026
Pediatric Exclusivity (PED) Jan 13, 2027

Drugs and Companies using REMDESIVIR ingredient

NCE-1 date: 2026-01-13

Market Authorisation Date: 22 October, 2020

Treatment: NA

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

More Information on Dosage

VEKLURY family patents

Family Patents

67. Vevye patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11413323 NOVALIQ GMBH Ophthalmic composition for treatment of dry eye disease
Oct, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) May 30, 2026

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 30 May, 2023

Treatment: Treatment of dry eye disease (ded)

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

VEVYE family patents

Family Patents

68. Vtama patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590088 DERMAVANT SCI Use of Tapinarof for the treatment of chronic plaque psoriasis
Nov, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 23, 2027

Drugs and Companies using TAPINAROF ingredient

NCE-1 date: 2026-05-23

Market Authorisation Date: 23 May, 2022

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: CREAM;TOPICAL

More Information on Dosage

VTAMA family patents

Family Patents

69. Vuity patents expiration

VUITY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610518 ABBVIE INC Presbyopia treatments
Apr, 2039

(15 years from now)

US11285134 ABBVIE INC Presbyopia treatments
Apr, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule (D) Mar 28, 2026
New Product (NP) Oct 28, 2024

Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 October, 2021

Treatment: Use of vuity for the treatment of presbyopia in adults

Dosage: SOLUTION;OPHTHALMIC

How can I launch a generic of VUITY before it's drug patent expiration?
More Information on Dosage

VUITY family patents

Family Patents

70. Wynzora patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11638711 MC2 NA
Mar, 2039

(15 years from now)

US11696919 MC2 Topical composition
Mar, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form (NDF) Jul 20, 2023

Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient

Market Authorisation Date: 20 July, 2020

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage

WYNZORA family patents

Family Patents

71. Xarelto patents expiration

XARELTO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10828310 JANSSEN PHARMS Reducing the risk of cardiovascular events
Jan, 2039

(14 years from now)

US10828310

(Pediatric)

JANSSEN PHARMS Reducing the risk of cardiovascular events
Jul, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Aug 23, 2024
Pediatric Exclusivity (PED) Feb 23, 2025

Drugs and Companies using RIVAROXABAN ingredient

Market Authorisation Date: 01 July, 2011

Treatment: Reduction of risk of cardiovascular death, myocardial infarction, and stroke in patients with cad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-10...

Dosage: TABLET;ORAL

How can I launch a generic of XARELTO before it's drug patent expiration?
More Information on Dosage

XARELTO family patents

Family Patents

72. Xcopri patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11654133 SK LIFE Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy
Jun, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 10, 2025

Drugs and Companies using CENOBAMATE ingredient

NCE-1 date: 2024-03-10

Market Authorisation Date: 10 March, 2020

Treatment: Co-administration of cenobamate with phenobarbital and/or phenytoin for the treatment of partial onset seizures

Dosage: TABLET;ORAL

More Information on Dosage

XCOPRI family patents

Family Patents

73. Yupelri patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11484531 MYLAN IRELAND LTD NA
Oct, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 9, 2023

Drugs and Companies using REVEFENACIN ingredient

NCE-1 date: 2022-11-09

Market Authorisation Date: 09 November, 2018

Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: SOLUTION;INHALATION

How can I launch a generic of YUPELRI before it's drug patent expiration?
More Information on Dosage

YUPELRI family patents

Family Patents

74. Zejula patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11730725 GLAXOSMITHKLINE Niraparib formulations
Jan, 2039

(14 years from now)

Drugs and Companies using NIRAPARIB TOSYLATE ingredient

Market Authorisation Date: 26 April, 2023

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

ZEJULA family patents

Family Patents

75. Zepbound patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Nov 8, 2026
New Chemical Entity Exclusivity (NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 2026-05-13

Market Authorisation Date: 08 November, 2023

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

ZEPBOUND family patents

Family Patents

76. Zimhi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11027072 ADAMIS PHARMS CORP Emergency devices
May, 2039

(15 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2021

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

ZIMHI family patents

Family Patents

List of large molecules

1. List of Eylea large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US10973879 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
May, 2039

(15 years from now)

US11160918 REGENERON PHARMACEUTICALS, INC. Medical device packaging and related methods
Jul, 2039

(15 years from now)

Ingredients: AFLIBERCEPT